In one aspect, the present disclosure is directed to a method for preventing or treating a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a hyperimmunized egg product obtained from an egg-producing animal, thereby preventing or treating coronavirus infection in the subject, wherein the hyperimmunized egg product comprises a therapeutically effective amount of one or more antibodies to the coronavirus. The present disclosure is also directed to hyperimmunized eggs and egg products produced by an animal that has been hyperimmunized with an antigen selected from i) a spike (S) protein, an S1 subunit protein, an S2 subunit protein, a receptor binding domain (RBD), and an immunogenic fragment thereof; ii) a nucleocapsid (N) protein, and an immunogenic fragment thereof; iii) a human ACE2 receptor protein, and an immunogenic fragment thereof; and iv) a human coronavirus selected from the group consisting of SARS-CoV, MERS-CoV, SARS-CoV-2, HCoV-HKU1, HCoV-NL63, HCoV-OC43 and HCoV-229E. Methods of preparing the hyperimmunized eggs and egg products are also disclosed.

Described herein are peptides from secretory phospholipase A.sub.2-IB and antibodies that can be used to reduce the contribution of the gastrointestinal tract to inflammatory processes including systemic inflammatory responses. Specifically, antibodies that bind specifically a peptide from secretory phospholipase A.sub.2-IB prevent death in a mouse model of LPS-induced endotoxemia. The antibodies described herein are particularly useful to treat systemic inflammatory response syndromes, including sepsis.

Methods for producing mono-specific immunoglobin Y (IgY) antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are disclosed. IgY antibodies are found in birds and can be isolated from egg yolk of chicken eggs. Hens are immunized with a SARS-CoV-2 spike protein comprising an ACE2 receptor binding domain (RBD). IgY antibodies against the RBD are isolated from eggs laid by the hens. The isolated RBD-IgY antibodies were tested in vitro in mammalian cells, wherein the RBD-IgY blocked SARS-CoV-2 infection of the cells. A pharmaceutical composition comprising the mono-specific IgY antibodies can be used to inhibit or treat COOVID-19, the SARS-CoV-2 infection. IgY antibodies are generally regarded as safe and offer various production and treatment advantages when compared to mammalian antibodies.

A prophylactic and/or therapeutic food composition for control of bacterial and/or fungal infection in bees and/or bee larvae, and methods of using and making the same. Bee feed compositions comprising bacterial and/or fungal antibodies dispersed in an edible base composition. Use of bacterial and/or fungal antigenic agents to passively generate bacterial and/or fungal antibodies in chicken egg yolks, and use of such bacterial and/or fungal antibodies for prophylaxis or treatment of bacterial and/or fungal infection in the bees and/or larvae.

In one aspect, a formulation comprising (a) an antibody that specifically binds an enterotoxigenic Escherichia coli (ETEC) or a molecule produced by an ETEC and (b) an antibody that specifically binds a norovirus (NV) or epitope thereof, is provided. In another aspect, a method of treating or preventing Travelers' diarrhea using the formulation is provided.

For many diseases due to microbes or the like, proliferation of microbes themselves is a cause of a symptom. However, there were cases where a substance released by the microbes is a cause of a symptom. In such cases, when attempting to treat a disease with an antibody, it was necessary to obtain an antibody against an antigen that is a substance causing the disease. However, it was difficult to find the underlying substance causing the disease among substances released by the microbes. An antibody (polyclonal) binding to not only an antigen but also to a substance, which is secreted by the antigen and accelerates the deterioration of a symptom, is obtained by immunizing birds with a lysis solution produced from lysing microbial cells as an antigen. Further, an antibody obtained with a surface protein of a virus as an antigen is expected to inhibit an infection by a virus.

Described herein are methods of reducing Salmonella in the intestines of poultry in need thereof by administering to a poultry bird an effective amount of an interleukin-10 peptide or an isolated antibody that specifically binds an interleukin-10 peptide. Administering may be performed within 1 to 4 weeks of harvest of the poultry in order to reduce Salmonella transmission to human consumers. Also included herein are finishing feeds that include an interleukin-10 peptide or an isolated antibody that specifically binds an interleukin-10 peptide.

Disclosed herein are methods of controlling parasitic worms in herbivorous mammals and other species by orally administering an isolated antibody that specifically binds the interleukin-10 peptide or an interleukin-10 peptide. In the case of herbivorous mammals such as cattle, for example, administration of the anti-IL-10 antibodies increases weight gain and increases feed efficiency in the animals.

A novel class or family of TGF-β binding proteins is disclosed. Also disclosed are assays for selecting molecules for increasing bone mineralization and methods for utilizing such molecules.

A stomatological composition is provided. The stomatological composition is capable of stably compounding an antibody obtained from a hen egg yolk, and preventing diseases in an oral cavity such as odontonecrosis and periodontal disease from occurring, or improving such diseases in the oral cavity. The stomatological composition includes at least one selected from the group consisting of lipase, protease and the antibody obtained from the hen egg yolk, citric acid and a metal salt of citric acid. A total amount of the lipase, the protease and the antibody obtained from the hen egg yolk is in the range of 0.001 to 10 wt %. When an amount of the citric acid is defined as “A” [wt %] and an amount of the metal salt of citric acid is defined as “B” [wt %], the following relation is satisfied: 0.005≦A/B≦1. Further, the stomatological composition of the present invention includes a polyglyceryl fatty acid ester or an amino acid-based ampholytic surfactant as a surfactant. Further, the stomatological composition of the present invention includes a collagen.